Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10213363 | International Journal of Cardiology | 2018 | 23 Pages |
Abstract
Among patients with AF and stable CAD >1-year after the index event, the addition of antiPLT to OAC does not apparently provide added protection against coronary events, but increases major bleeding. OAC monotherapy should thus be considered the antithrombotic therapy of choice for such patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Giuseppe Patti, Ladislav Pecen, Markus Lucerna, Kurt Huber, Miklos Rohla, Giulia Renda, Jolanta Siller-Matula, Renate B. Schnabel, Roberto Cemin, Paulus Kirchhof, Raffaele De Caterina,